Therapeutic management of metabolic dysfunction associated steatotic liver disease
United European Gastroenterology Journal · 2024-03 · 12 (2) · 177-186
DOI: 10.1002/ueg2.12525 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, online erschienen am 09.01.2024. Verfasst von Jing Zeng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Bariatric Surgery. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The incidence and prevalence of non‐alcoholic fatty liver disease (NAFLD) have been steadily increasing worldwide, with a huge societal and economic burden. Recently, NAFLD and non‐alcoholic steatohepatitis have been renamed and redefined as metabolic dysfunction associated steatotic liver disease (MASLD) and steatohepatitis (Metabolic Dysfunction Associated Steatohepatitis (MASH)), which result from an imbalance between metabolic and inflammatory stress (mainly as a consequence of adipose tissue dysfunction and insulin resistance) and the defence and repair mechanisms of the steatotic liver. Once MASLD progresses to end‐stage of liver disease, treatment efficacy becomes limited and may require liver transplantation. Early detection and intervention are crucial. Lifestyle modification is consequently the cornerstone of its management. Timely consideration of bariatric surgeries should be given to patients meeting specific criteria. A multidisciplinary approach is warranted, starting from the concept that MASLD/MASH is at the centre of the cardiovascular‐liver‐metabolic syndrome. In some cases, pharmacological treatment can complement lifestyle modification. Several drugs used to treat the cardiometabolic co‐morbidities have some potential efficacy in slowing Down disease progression, and some have demonstrated efficacy on histological endpoints that are likely to translate into long‐term clinical benefits. Optimising the use of these drugs within their licenced indications is thus paramount for patients with MASLD. Several MASH‐specific drugs are on the horizon and are likely to enrich our therapeutic armamentarium in the near future, particularly in non‐cirrhotic stages of the disease. Much work still needs to be done to understand the specific features of MASH cirrhosis and develop efficacious treatments for this disease stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China.
- Department of Gastroenterology Hepatology, Antwerp University Hospital, Edegem, Belgium.
- InflaMed Centre of Excellence, Laboratory for Experimental Medicine and Paediatrics, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgiu…
ORCID-Profile: Jing Zeng, Sven M Francque
Zitieren
APA
Zeng, J., Fan, J. G., & Francque, S. M. (2024). Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterology Journal, 12(2), 177-186. https://doi.org/10.1002/ueg2.12525
Vancouver
Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterology Journal. 2024;12(2):177-186. doi:10.1002/ueg2.12525
BibTeX
@article{Zeng2024,
author = {Zeng, Jing and Fan, Jian-Gao and Francque, Sven M},
title = {Therapeutic management of metabolic dysfunction associated steatotic liver disease},
journal = {United European Gastroenterology Journal},
year = {2024},
volume = {12},
number = {2},
pages = {177--186},
doi = {10.1002/ueg2.12525}
}
EUVIMED